衡量和展示整个药品生命周期中患者参与的价值:患者参与影响衡量框架

Beyza Klein, Eleanor M. Perfetto, Elisabeth M. Oehrlein, Fay Weston, Trudie C. A. Lobban, Marc Boutin
{"title":"衡量和展示整个药品生命周期中患者参与的价值:患者参与影响衡量框架","authors":"Beyza Klein, Eleanor M. Perfetto, Elisabeth M. Oehrlein, Fay Weston, Trudie C. A. Lobban, Marc Boutin","doi":"10.1007/s40271-024-00713-7","DOIUrl":null,"url":null,"abstract":"<p>As the pharmaceutical industry advances towards more patient-focused product development, it is well recognized that meaningful patient engagement is required for the authentic patient voice to inform research and regulatory decisions. However, for this to happen systematically and consistently across the industry, there is still a need to evaluate and communicate the value of patient engagement to all stakeholders. Evaluating engagement also informs process improvement, elevating the value further. We describe the development of a conceptual, yet practical, framework for measuring the impact of engagement to achieve this. The framework depicts how metrics can be used to capture and assess the inputs, outputs, and value of patient engagement across the medicines lifecycle. Although conceived in the context of systems and processes within one company, Novartis, the framework was co-created with patient advisors and designed to be both patient-relevant and adaptable for any pharmaceutical organization. The adoption and evolution of the framework will help to demonstrate the value—to patients, healthcare systems, and businesses—of integrating patient engagement into core activities across the medicines lifecycle. We encourage the pharmaceutical industry to apply impact measurement to build a robust evidence base, through measuring, publishing, and communicating the value of patient engagement.</p>","PeriodicalId":501651,"journal":{"name":"The Patient - Patient-Centered Outcomes Research","volume":"72 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Measuring and Demonstrating the Value of Patient Engagement Across the Medicines Lifecycle: A Patient Engagement Impact Measurement Framework\",\"authors\":\"Beyza Klein, Eleanor M. Perfetto, Elisabeth M. Oehrlein, Fay Weston, Trudie C. A. Lobban, Marc Boutin\",\"doi\":\"10.1007/s40271-024-00713-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>As the pharmaceutical industry advances towards more patient-focused product development, it is well recognized that meaningful patient engagement is required for the authentic patient voice to inform research and regulatory decisions. However, for this to happen systematically and consistently across the industry, there is still a need to evaluate and communicate the value of patient engagement to all stakeholders. Evaluating engagement also informs process improvement, elevating the value further. We describe the development of a conceptual, yet practical, framework for measuring the impact of engagement to achieve this. The framework depicts how metrics can be used to capture and assess the inputs, outputs, and value of patient engagement across the medicines lifecycle. Although conceived in the context of systems and processes within one company, Novartis, the framework was co-created with patient advisors and designed to be both patient-relevant and adaptable for any pharmaceutical organization. The adoption and evolution of the framework will help to demonstrate the value—to patients, healthcare systems, and businesses—of integrating patient engagement into core activities across the medicines lifecycle. We encourage the pharmaceutical industry to apply impact measurement to build a robust evidence base, through measuring, publishing, and communicating the value of patient engagement.</p>\",\"PeriodicalId\":501651,\"journal\":{\"name\":\"The Patient - Patient-Centered Outcomes Research\",\"volume\":\"72 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Patient - Patient-Centered Outcomes Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s40271-024-00713-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Patient - Patient-Centered Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40271-024-00713-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

随着制药行业朝着更加以患者为中心的产品开发方向迈进,人们普遍认识到,要让研究和监管决策了解真实的患者声音,就需要有意义的患者参与。然而,要在整个行业内系统、一致地实现这一目标,仍需要对患者参与的价值进行评估,并将其传达给所有利益相关者。评估参与度还能为流程改进提供信息,从而进一步提升参与度的价值。为实现这一目标,我们介绍了一个概念性但实用的框架,用于衡量参与的影响。该框架描述了如何使用衡量标准来获取和评估整个药品生命周期中患者参与的投入、产出和价值。虽然该框架是在诺华一家公司的系统和流程背景下构思的,但它是与患者顾问共同创建的,其设计既与患者相关,又适用于任何制药机构。该框架的采用和发展将有助于证明将患者参与融入整个药品生命周期的核心活动对患者、医疗保健系统和企业的价值。我们鼓励制药行业通过衡量、发布和宣传患者参与的价值,应用影响衡量来建立强大的证据基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Measuring and Demonstrating the Value of Patient Engagement Across the Medicines Lifecycle: A Patient Engagement Impact Measurement Framework

Measuring and Demonstrating the Value of Patient Engagement Across the Medicines Lifecycle: A Patient Engagement Impact Measurement Framework

As the pharmaceutical industry advances towards more patient-focused product development, it is well recognized that meaningful patient engagement is required for the authentic patient voice to inform research and regulatory decisions. However, for this to happen systematically and consistently across the industry, there is still a need to evaluate and communicate the value of patient engagement to all stakeholders. Evaluating engagement also informs process improvement, elevating the value further. We describe the development of a conceptual, yet practical, framework for measuring the impact of engagement to achieve this. The framework depicts how metrics can be used to capture and assess the inputs, outputs, and value of patient engagement across the medicines lifecycle. Although conceived in the context of systems and processes within one company, Novartis, the framework was co-created with patient advisors and designed to be both patient-relevant and adaptable for any pharmaceutical organization. The adoption and evolution of the framework will help to demonstrate the value—to patients, healthcare systems, and businesses—of integrating patient engagement into core activities across the medicines lifecycle. We encourage the pharmaceutical industry to apply impact measurement to build a robust evidence base, through measuring, publishing, and communicating the value of patient engagement.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信